Format

Send to

Choose Destination
Hematol Oncol. 2019 Apr 23. doi: 10.1002/hon.2622. [Epub ahead of print]

Emerging translational science discoveries, clonal approaches and treatment trends in chronic myeloproliferative neoplasms.

Author information

1
Tufts University Cancer Center, Boston, MA, USA.
2
MD Anderson Cancer Center, Houston, TX, USA.
3
Fred Hutchinson Cancer Center, Seattle, WA, USA.
4
University of Utah, Salt Lake City, UT, USA.
5
Weill Cornell Medicine, New York, NY, USA.
6
Hôpital Saint-Louis, Paris, France.
7
Stanford Cancer Institute, Stanford, CA, USA.
8
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria.
9
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria.
10
Chang-Gung Memorial Hospital, Chiayi.
11
College of Medicine, Chang-Gung University, Taoyuan, Taiwan.
12
Foundation for Clinical Research (FROM), Papa Giovanni XXIIII Hospital, Bergamo, Italy.
13
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
14
University Medical Center RWTH Aachen, Aachen, Germany.
15
Orbassano University Hospital, Turin, Italy.
16
University of California Irvine, Irvine, CA, USA.

Abstract

The 60th American Society of Hematology (ASH) held in San Diego in December 2018 was followed by the 13th Post-ASH chronic myeloproliferative neoplasms (MPNs) workshop on the 4th -5th December 2018. This closed annual workshop, first introduced in 2006 by Goldman and Mughal, was organized in collaboration with Alpine Oncology Foundation and allowed experts in preclinical and clinical research in the chronic MPNs to discuss the current scenario, including relevant presentations at ASH, and address pivotal open questions that impact translational research and clinical management. This review is based on the presentations and deliberations at this workshop, and rather than provide a resume of the proceedings, we have selected some of the important translational science and treatment issues which require clarity. We discuss the experimental and observational evidence to support the intimate interaction between aging, inflammation, and clonal evolution of MPNs, the clinical impact of the unfolding mutational landscape on the emerging targets and treatment of MPNs, new methods to detect clonal heterogeneity, the challenges in managing childhood and adolescent MPN, and reflect on the treatment of systemic mastocytosis (SM) following the licensing of midostaurin.

KEYWORDS:

Clonal heterogeneity; IFNα; Inflammaging; Investigational therapies; MPNs

PMID:
31013548
DOI:
10.1002/hon.2622

Supplemental Content

Loading ...
Support Center